Analysts Set ALX Oncology Holdings Inc. (NASDAQ:ALXO) Target Price at $4.14

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has been assigned an average recommendation of “Moderate Buy” from the seven analysts that are currently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $4.14.

Several research analysts have recently commented on ALXO shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of ALX Oncology in a report on Friday, January 24th. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of ALX Oncology in a research note on Friday, March 7th. UBS Group dropped their price objective on ALX Oncology from $4.00 to $2.20 and set a “buy” rating for the company in a research note on Monday, January 27th. Stifel Nicolaus decreased their target price on shares of ALX Oncology from $3.00 to $1.50 and set a “hold” rating on the stock in a research note on Friday, March 7th. Finally, Jefferies Financial Group upgraded shares of ALX Oncology from a “hold” rating to a “buy” rating and upped their price target for the company from $2.00 to $3.00 in a report on Thursday, March 6th.

ALX Oncology Price Performance

Shares of NASDAQ:ALXO opened at $0.96 on Friday. The company has a quick ratio of 4.82, a current ratio of 4.82 and a debt-to-equity ratio of 0.07. The stock has a market cap of $50.60 million, a PE ratio of -0.32 and a beta of 1.01. The company’s fifty day moving average is $1.34 and its 200 day moving average is $1.58. ALX Oncology has a 52 week low of $0.89 and a 52 week high of $17.83.

Hedge Funds Weigh In On ALX Oncology

Hedge funds and other institutional investors have recently made changes to their positions in the business. JSF Financial LLC purchased a new position in ALX Oncology during the 4th quarter valued at $29,000. GSA Capital Partners LLP bought a new stake in shares of ALX Oncology during the 3rd quarter valued at about $88,000. Barclays PLC increased its position in shares of ALX Oncology by 243.6% during the third quarter. Barclays PLC now owns 59,502 shares of the company’s stock valued at $107,000 after buying an additional 42,185 shares during the period. Sei Investments Co. bought a new position in ALX Oncology in the fourth quarter worth about $102,000. Finally, Bridgeway Capital Management LLC purchased a new stake in ALX Oncology in the fourth quarter worth about $125,000. Institutional investors own 97.97% of the company’s stock.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.